| May IL-17 have a role in COVID-19 infection? #MMPMID32339777Megna M; Napolitano M; Fabbrocini GMed Hypotheses 2020[Jul]; 140 (ä): 109749 PMID32339777show ga
ä|*Betacoronavirus[MESH]|*Pandemics[MESH]|Animals[MESH]|Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use[MESH]|COVID-19[MESH]|COVID-19 Drug Treatment[MESH]|Coronavirus Infections/complications/drug therapy/*physiopathology[MESH]|Cytokine Release Syndrome/drug therapy/*etiology/physiopathology[MESH]|Humans[MESH]|Influenza, Human/physiopathology[MESH]|Interleukin-17/antagonists & inhibitors/*physiology[MESH]|Interleukin-6/physiology[MESH]|Mice[MESH]|Mice, Knockout[MESH]|Models, Immunological[MESH]|Multiple Organ Failure/etiology/prevention & control[MESH]|Orthomyxoviridae Infections/physiopathology[MESH]|Pneumonia, Viral/complications/drug therapy/*physiopathology[MESH]|Receptors, Interleukin-17/deficiency[MESH]
DeepDyve Pubget Overpricing |
|